An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for ...

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively ...

Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical ...

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement: Acelyrin stockholders will now receive 0.4814 shares of Alumis common ...

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision ...